🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: UMEC

Found 50 matching trials

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

Batefenterol is a novel bifunctional molecule that combines muscarinic anta...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-11-06

Trial ID

NCT02570165

Treatments Being Tested

Batefenterol Umeclidinium/ Vilanterol Placebo

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

PHASE1

This will be a randomized, double-blind, single-dose, three-period balanced...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-11-08

Trial ID

NCT01725685

Treatments Being Tested

FF 400 mcg UMEC 500 mcg FF/UMEC 400/500 mcg

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

PHASE3

The primary objective is to compare the efficacy of UMEC/VI Inhalation Powd...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-15

Trial ID

NCT01899742

Treatments Being Tested

Umeclidinium/Vilanterol 62.5/25 mcg Tiotropium 18 mcg

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This study is a 12-week, multicenter, randomized, double blind, parallel gr...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-01

Trial ID

NCT02152605

Treatments Being Tested

UMEC/VI Placebo

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

This is a multicenter, randomized, double-blind, placebo-controlled, 2-peri...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-01-23

Trial ID

NCT02275052

Treatments Being Tested

UMEC/VI DPI Placebo DPI Albuterol/salbutamol MDI

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

PHASE4

The primary objective of this study is to assess the effect of umeclidinium...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-07-14

Trial ID

NCT02799784

Treatments Being Tested

UMEC/VI TIO/OLO Albuterol/salbutamol

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

PHASE3

The study aims to evaluate the efficacy, safety and tolerability of FF/UMEC...

Status

Completed

Location

GSK Investigational Site

Start Date

2021-07-29

Trial ID

NCT04937387

Treatments Being Tested

FF/VI FF/UMEC/VI ELLIPTA

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The primary purpose of this study is to evaluate lung function and health r...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-06-25

Trial ID

NCT03478696

Treatments Being Tested

budesonide/formoterol albuterol/salbutamol FF/UMEC/VI Placebo to match budesonide/formoterol tiotropium Placebo to match FF/UMEC/VI placebo to match tiotropium ELLIPTA MDI HandiHaler

Previous Next